Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Rang in Aktien
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Aktienkurs
$4.48
Marktkapitalisierung
$4.99B
Veränderung (1 Tag)
-5.20%
Veränderung (1 Jahr)
-41.89%
Land
CN
Handel Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Anzahl der ausstehenden Aktien zum June 2026: 1.11B
Laut den neuesten Finanzberichten und dem Aktienkurs von Shenzhen Salubris Pharmaceuticals Co., Ltd. beträgt die aktuelle Anzahl der ausstehenden Aktien 1.11B. Am Ende von December 2024 hatte das Unternehmen 1.11B ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) von 2006 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 1.11B | -0.34% |
| 2025 | 1.11B | 0.07% |
| 2024 | 1.11B | -0.13% |
| 2023 | 1.12B | 1.55% |
| 2022 | 1.10B | 2.90% |
| 2021 | 1.07B | 3.79% |
| 2020 | 1.03B | -1.35% |
| 2019 | 1.04B | -0.33% |
| 2018 | 1.05B | 0.14% |
| 2017 | 1.04B | -0.14% |
| 2016 | 1.05B | 0.00% |
| 2015 | 1.05B | 0.36% |
| 2014 | 1.04B | -0.37% |
| 2013 | 1.05B | -0.14% |
| 2012 | 1.05B | 0.17% |
| 2011 | 1.05B | 0.15% |
| 2010 | 1.04B | 22.89% |
| 2009 | 849.71M | 8.80% |
| 2008 | 780.97M | -0.36% |
| 2007 | 783.76M | 19.22% |
| 2006 | 657.38M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 349.00M | -68.59% |
US
|
|
| 461.20M | -58.49% |
FR
|
|
| - | - |
JP
|
|
| 274.79M | -75.27% |
US
|
|
| - | - |
CH
|
